Seagen Inc.
- Country
- ๐บ๐ธUnited States
- Ownership
- Public, Subsidiary
- Established
- 1998-01-01
- Employees
- 3.2K
- Market Cap
- -
- Website
- http://www.seagen.com
FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung Carcinoma
- Conditions
- First Posted Date
- 2004-07-02
- Last Posted Date
- 2011-10-24
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00086333
- Locations
- ๐บ๐ธ
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
๐บ๐ธProvidence Health System, Regional Cancer Program, Portland, Oregon, United States
๐บ๐ธUniversity of Chicago, Chicago, Illinois, United States
Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma
- Conditions
- First Posted Date
- 2004-03-16
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT00079755
- Locations
- ๐บ๐ธ
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
๐บ๐ธUniversity of Washington, Seattle, Washington, United States
๐บ๐ธUniversity of Califorinia at Los Angeles, Los Angeles, California, United States
Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma
- First Posted Date
- 2004-03-16
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT00079716
- Locations
- ๐บ๐ธ
The Cleveland Clinic, Cleveland, Ohio, United States
๐บ๐ธJames R. Berenson M.D., Inc., West Hollywood, California, United States
๐บ๐ธDana Farber Cancer Institute, Boston, Massachusetts, United States
Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer
- Conditions
- First Posted Date
- 2003-06-27
- Last Posted Date
- 2011-10-24
- Lead Sponsor
- Seagen Inc.
- Registration Number
- NCT00028483
- Locations
- ๐บ๐ธ
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies
- Conditions
- First Posted Date
- 2003-01-15
- Last Posted Date
- 2011-10-12
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT00051597
- Locations
- ๐บ๐ธ
University of Rochester, Rochester, New York, United States
๐บ๐ธMD Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธUniversity of Washington, Seattle, Washington, United States
Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer
- Conditions
- First Posted Date
- 2003-01-15
- Last Posted Date
- 2011-10-24
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00051584
- Locations
- ๐บ๐ธ
California Hematology Oncology Medical Group, Torrance, California, United States
๐บ๐ธVirginia Mason Medical Center, Seattle, Washington, United States
๐บ๐ธMountain States Tumor Institute, Boise, Idaho, United States
Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung Carcinoma
- Conditions
- First Posted Date
- 2003-01-15
- Last Posted Date
- 2011-10-24
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00051571
- Locations
- ๐บ๐ธ
University of Chicago, Chicago, Illinois, United States
๐บ๐ธFlorida Cancer Specialists, Fort Myers, Florida, United States
๐บ๐ธVirginia Mason Research Center, Seattle, Washington, United States
Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer
- Conditions
- First Posted Date
- 2002-02-28
- Last Posted Date
- 2011-10-24
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT00031187
- Locations
- ๐บ๐ธ
Bendheim Cancer Center, Greenwich, Connecticut, United States
๐บ๐ธArlington Fairfax Hematology-Oncology, P.C., Arlington, Virginia, United States
๐บ๐ธInnovative Medical Research of South Florida, Miami Shores, Florida, United States